Enhancing Vision Outcomes with Innovative Therapies in Neovascular AMD and DME

Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, provide an overview of the effect of anti-VEGF treatment in neovascular age-related macular degeneration and diabetic macular edema.

Retina experts discuss treatment of wet AMD, focusing on frequency of treatment and treatment breaks, and fluid tolerance.

Drs Nathan Steinle, Adrienne Scott, and Carl Regillo comment on the phase 3 trial outcomes of faricimab in neovascular AMD.

Expert retina specialists discuss the use of faricimab and dosing for the treatment of neovascular age-related macular degeneration in the clinical practice setting.

Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, discuss patient selection for faricimab in neovascular AMD, as well as approaches to switching to faricimab after a poor response to other treatment.

Expert retina specialists review the safety profile of faricimab compared with other anti-VEGF therapies in AMD.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao share their approaches to dosing recommendations for faricimab in the treatment of neovascular AMD.

Retina experts discuss biomarkers to track disease progression in neovascular AMD, as well as their thoughts on the utility of optical coherence tomography angiography (OCT-A).

Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, review the challenges presented in the management of DME, including the disease burden on the patient.

Carl Regillo, MD, FACS, FASRS, and Prethy Rao, MD, MPH, discuss the phase 3 trials of faricimab in the treatment of DME and highlighting the enhanced resolution of intraocular fluid.

Expert retina specialists provide an overview of the YOSEMITE and RHINE clinical studies of faricimab in the treatment of DME.

Retina experts discuss the benefits of using intraocular steroids to treat patients with DME as well as their approach to switching to steroids after a poor response to anti-VEGF therapy.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao comment on loading dose recommendations for faricimab or other anti-VEGF therapies in the treatment of DME.

Retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301.

Expert retina specialists discuss the OPT-302 study and the challenges presented when using 2 agents in tandem to treat diabetic macular edema.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao highlight gene therapy as a future treatment of neovascular AMD and DME and how it will significantly reduce the burden on patients.

Adrienne Scott, MD, and Prethy Rao, MD, MPH, discuss implementation of step therapy in neovascular age-related macular degeneration and diabetic macular edema without compromising vision outcomes.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao share their perspectives on biosimilars in the treatment of neovascular AMD and DME, emphasizing how their cost will affect their uptake.

Expert retina specialists discuss recent developments in the treatment landscape for geographic atrophy (GA) and the future management of patients with coexisting neovascular AMD and GA.

Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.

A panel of retina specialists weighed in on the dosing intervals when using of faricimab for the treatment of neovascular AMD in the clinical practice setting. Do you agree with them?

A panel of retina experts discussed the challenges presented in the management of DME. Which do you think is the biggest of these challenges?

In recent panel discussions, leaders in the retina space shared their thoughts around AMD and DME. These key quotes showcase the heart of these discussions.

A panel of retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301. Which emerging treatments are you most interested in?